Anuraag Bukkuri

This paper develops an evolutionary model to show how cancer evolvability affects therapy outcomes, finding that targeted therapy is better for low-evolvability cancers and chemotherapy for high-evolvability ones, with a combined approach effective against facultative evolvability.

The paper identifies two distinct p21-driven pathways to whole-genome duplication in breast cancer cells, both converging on a CDK4/6-dependent polyploid G0 state, and shows that CDK4/6 inhibitors can block WGD and enhance therapy efficacy.